First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.

Key facts

Study ID

NCT01469052

Run by

Pfizer

People needed

36

Starts

2002-11-01

Expected to finish

2004-08-01

Last updated by the study team

2012-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with cytologically or histologically confirmed solid tumor(s) and with at least one measurable disease site
• Patients with adequate bone marrow, liver and kidney function
• Patients with life expectancy of at least 12 weeks

You may not qualify if…

• Patients who have received chemotherapy, immunotherapy, radiotherapy or any investigational agent within 4 weeks of study entry
• Patients with have had a major surgical procedure within 4 weeks of study entry

Where it is running

• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.